Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: A single-center experience and a critical review of the literature

Anti-Cancer Drugs

Volumn 24, Issue 1, 2013, Pages 90-97

  Lombardi, Giuseppe ^a   Zustovich, Fable ^a   Farina, Patrizia ^a   Fiduccia, Pasquale ^a   Della Puppa, Alessandro ^c   Polo, Valentina ^a   Bertorelle, Roberta ^b   Gardiman, Marina P ^d   Banzato, Alberto ^a   Ciccarino, Pietro ^c   Denaro, Luca ^e   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Departments of Molecular Immunology and Oncology   (Italy)

^c Department of Neurosurgery ^*  (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiangiogenic drug; Bevacizumab; Biomarker; Glioblastoma; Hypertension; Sorafenib

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GADOLINIUM; IRINOTECAN; SORAFENIB; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD PRESSURE; CANCER CONTROL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD PRESSURE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870931206     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835aa5fd     Document Type: Review

References (16)

1. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGFtargeting therapies: current evidence and handling strategies. Oncologist 2010; 15:683-694.
2. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20:227-230.
3. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103:763-773.
4. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011; 16:1325-1332.
5. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963-1972.
6. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
8. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2010; 29:142-148.
9. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011; 101:57-66.
10. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009; 20:393-394.
11. Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T. The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2011; 29 (Suppl):2021.
12. Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 2010; 97:157-158.
13. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
14. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neurooncol 2011; 13: 143-151.
15. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-2823.
16. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:2712-2718.